Pfizer-BioNTech’s bivalent COVID-19 vaccine may not protect cancer patients from the most common omicron subvariant in circulation now, a study suggests.
All articles by Laura M. Healy
-
Latest News Your top articles for Sunday
For More Personalized News -
Haymarket Medical NetworkTop Picks
- Loading...
Continuing Medical Education (CME/CE) Courses